FORTUNE -- Every smart investors knows you should aim to buy low and sell high, so why is the concept lost on managers of public companies?
As Will Becker, analyst at Behind the Numbers, shows in a new report to clients on the trend of increased share buybacks, when company management buys back its own stock, it tends to do it when market valuations are high, not low. And that's exactly what's happened over the past year as the S&P 500 repeatedly reached new heights.
According to data assembled by Becker, S&P 500 companies increased the total dollar amount of share buybacks they engaged in by 28.5% year-over-year in the fourth quarter of 2013, to $126 billion. "While this represents a sequential increase of just 1.7% from 3Q13, S&P 500 companies have been more active over the trailing twelve months ended 12/31/13 than in any period since the financial crisis," he writes.
A few more stats from Becker's report:
Defenders of share buyback schemes often point to the fact that a buyback can help companies and investors reduce their tax liabilities. For instance, a company can borrow money to repurchase shares and deduct the interest paid on debt. At the same time, some investors would rather their investments appreciate through share buybacks than receive a dividend because they must immediately pay taxes on dividends but not gains on stock they haven't sold.
Others argue that share repurchases should be a natural step in a company's lifecycle. Firms competing in declining industries with few good capital investment options must find a way to return profits to their shareholders, and share buybacks are an effective way to wind down a struggling company in a way that keeps shareholders and executives happy.
But what about companies operating in arguably thriving industries, like pharmaceuticals, that will only grow more profitable as the population within wealthy nations ages? In his report, Becker fingers pharma company Pfizer (PFE) as one such firm with few good excuses for buying back so many of its shares. Pfizer has been hit hard by the expiration of patents on two of its best-selling drugs, Lipitor and Viagra, in recent years, and it has been, according to Becker, "scrambling" to replace that revenue with cost cutting, acquisitions, and restructuring of its R&D efforts.
But instead of pouring its profits into developing new drugs, Pfizer has been busy buying back huge amounts of its own stock -- $16.3 billion worth in 2013. Becker argues that the company's move may have as much to do with executives hoping to reduce the total number of shares in circulation so that they can meet certain stock-price based performance metrics as it has to do with the belief that Pfizer shares are undervalued. Writes Becker:
Looking at PFE's annual incentive program, a pool is funded based on the company's performance on three financial metrics: total revenue, adjusted diluted earnings per share and cash flow from operations ... largely with the aid of its record share repurchase activity, PFE managed to exceed the 2013 target goal fro adjusted diluted EPS, while producing slightly below-target performance for its revenue and cash flow metrics.
While Pfizer didn't have a particularly stellar 2013, its executives still received healthy bonuses, in part because Pfizer surpassed its goals for growth in earnings per share, a goal that wouldn't have been met without such a concerted effort to keep the total number of shares outstanding low. Meanwhile, Pfizer has reduced its investment in research and development as a percentage of revenue every year since 2007 -- which can't bode well for the company's prospects of launching the next Lipitor or Viagra.
Becker believes Autozone (AZO) is also a bit too fond of share buybacks and that its CEO William Rhodes stands to be a chief beneficiary of the strategy, as "a material amount of his future compensation is tied to diluted EPS targets." Like Pfizer, the money to buy back shares has forced Autozone to reduce investment elsewhere in the company as it has recently reported a cash flow deficit and has had to take on hundreds of millions of dollars in new debt.
Becker also points to companies like Sysco (SYY), Jarden (JAH), and Brinker International (EAT) as firms buying back for the wrong reasons, but there are surely many more out there. And as the stock market continues to rise, investors should be ever more wary of investing in companies that would rather buy back shares of their own stock at high valuations than invest in its business, the ostensible generator of capital gains.
If the benchmarks used to determine the value of securities were to suddenly reverse course, the "new normal" could soon be history.
By Shawn Tully, senior editor-at-large
FORTUNE -- Seldom have so many of the metrics that influence stock prices strayed so far from the long-term trends we've come to consider "normal." Corporate earnings are far above what's normal historically, interest rates are way below normal because of Fed intervention, and MOREMar 26, 2014 3:17 PM ET
Berkshire Hathaway's annual letter to shareholders has included pages on the stock market and where it's headed in previous years. This year? Silence.
FORTUNE -- The Oracle of Omaha's crystal ball must be cloudy these days.
In Warren Buffett's annual letter to Berkshire Hathaway (BRKA) shareholders, released Saturday morning, he says little about the stock market or where shares might be headed. Buffett does say, as he has in the past, that MOREStephen Gandel, senior editor - Mar 1, 2014 8:00 AM ET
Shares are down, but not the ones you would expect.
FORTUNE -- The recent stock selloff has people once again freaked out about the market. But perhaps it shouldn't.
CNNMoney's Fear & Greed Index is now again in extreme fear territory. A month ago, the gauge of investor sentiment was stuck on greed.
The conventional wisdom is that the selloff will be short-lived. The economy is strong. The stock market, which was up MOREStephen Gandel, senior editor - Feb 5, 2014 1:09 PM ET
The stock and bond markets have been moving in the same direction lately, and that has some worried.Stephen Gandel, senior editor - Dec 9, 2013 12:28 PM ET
In the Fed's mirror, a stock market bubble is appearing farther away than it may actually be.
Fortune -- At Thursday's confirmation hearing for Janet Yellen, the nominee to be the next Federal Reserve chairman was asked whether she thought there was a bubble in the stock market.
Yellen gave a pretty clear answer: No.
"Stock prices have risen pretty robustly," Yellen said. "But I think that if you look at traditional valuation MOREStephen Gandel, senior editor - Nov 15, 2013 12:04 PM ET
The ones that matter most to the market may not be as high as everyone assumes.
FORTUNE -- Over the past year or so, corporate profits have been a growing concern for investors. They're too good.
Margins, the percentage of each sale that ends up as profit, as measured by GDP, have never been this high. They hit a record near the beginning of 2011 and have continued to march up. At MOREStephen Gandel, senior editor - Sep 26, 2013 10:11 AM ET
More and more people are borrowing against their brokerage accounts to buy condos and expand their businesses. That's not reassuring.
FORTUNE -- Like the recent bull market? How about taking a home renovation to go with it? That apparently is what some investors have been doing with their stock gains.
The recent run-up in the market, financial advisers say, has led to a resurgence of the type of loan not seen since MOREStephen Gandel, senior editor - May 29, 2013 11:57 AM ET
Fewer Americans have a stake in the stock market, and unemployment may be preventing more from investing in equities.
FORTUNE – As U.S. stocks soar to new highs, economists argue the rally makes people feel richer. And when they think they're wealthier, the theory is that they'll spend more on everything from homes to cars and clothing.
The problem with that idea is fewer and fewer Americans actually have any stake in MORENin-Hai Tseng, Writer - May 15, 2013 11:36 AM ET
New York University economist Nouriel Roubini comes under fire for his bullish market call.
FORTUNE -- Recently the famously gloomy economist Nouriel Roubini has been talking up stocks. He says the Federal Reserve is pumping up the U.S. market and that the weak global economy will require it to do so for the next two years. That's an opportunity for anyone who has money in the market. After that, watch out.
But MOREStephen Gandel, senior editor - May 8, 2013 3:37 PM ET
|Will millennials kill Costco?|
|Pope Francis challenges the free market - The Buzz|
|Stocks: It's report card time on Wall Street|
|Nonprofits that pay top fundraisers $1 million (or more) a year|
|Americans have fallen in love with real estate once again|